WO2017105881A8 - Composés deutérés pour traiter la douleur - Google Patents

Composés deutérés pour traiter la douleur Download PDF

Info

Publication number
WO2017105881A8
WO2017105881A8 PCT/US2016/064812 US2016064812W WO2017105881A8 WO 2017105881 A8 WO2017105881 A8 WO 2017105881A8 US 2016064812 W US2016064812 W US 2016064812W WO 2017105881 A8 WO2017105881 A8 WO 2017105881A8
Authority
WO
WIPO (PCT)
Prior art keywords
treating pain
deuterated compounds
deuterated
compounds
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2016/064812
Other languages
English (en)
Other versions
WO2017105881A1 (fr
Inventor
Changfu CHENG
Chaoran HUANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NeuForm Pharmaceuticals Inc
Original Assignee
NeuForm Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NeuForm Pharmaceuticals Inc filed Critical NeuForm Pharmaceuticals Inc
Publication of WO2017105881A1 publication Critical patent/WO2017105881A1/fr
Publication of WO2017105881A8 publication Critical patent/WO2017105881A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne de nouveaux composés chimiques utiles pour traiter la douleur, ou une maladie ou un trouble associé à la douleur, ainsi qu'une composition pharmaceutique contenant ces composés, et des procédés de préparation et d'utilisation de ceux-ci.
PCT/US2016/064812 2015-12-15 2016-12-02 Composés deutérés pour traiter la douleur Ceased WO2017105881A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562267700P 2015-12-15 2015-12-15
US62/267,700 2015-12-15

Publications (2)

Publication Number Publication Date
WO2017105881A1 WO2017105881A1 (fr) 2017-06-22
WO2017105881A8 true WO2017105881A8 (fr) 2017-12-14

Family

ID=59057413

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/064812 Ceased WO2017105881A1 (fr) 2015-12-15 2016-12-02 Composés deutérés pour traiter la douleur

Country Status (1)

Country Link
WO (1) WO2017105881A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017106547A1 (fr) * 2015-12-17 2017-06-22 Trevena, Inc. Combinaisons de ligands de récepteurs opioïdes et d'inhibiteurs du cytochrome p450
CN109689646B (zh) * 2016-07-01 2022-09-02 纽弗姆制药有限公司 用于治疗疼痛的氘代化合物
WO2019158634A1 (fr) * 2018-02-16 2019-08-22 Esteve Pharmaceuticals, S.A. Dérivés deutérés de 9-(2,5-difluorophénéthyl)-4-éthyl-2-méthyl-1-oxa-4,9-diazaspiro[5.5]undécan-3-one
WO2023030319A1 (fr) * 2021-08-31 2023-03-09 天地恒一制药股份有限公司 Agoniste du récepteur opioïde, son procédé de préparation et son utilisation
CN118203578A (zh) * 2023-12-26 2024-06-18 天津市人民医院 奥赛利定在制备预防或治疗围术期低体温的药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10123129A1 (de) * 2001-05-02 2002-11-14 Berolina Drug Dev Ab Svedala Deuterierte 3-Piperidinopropiophenone sowie diese Verbindungen enthaltende Arzneimittel
SMT201700325T1 (it) * 2011-03-23 2017-09-07 Trevena Inc Ligandi del recettore degli oppioidi e metodi per l’uso e la produzione dei medesimi

Also Published As

Publication number Publication date
WO2017105881A1 (fr) 2017-06-22

Similar Documents

Publication Publication Date Title
IL285782A (en) Compounds, compositions, and methods for treating disease
IL269599B1 (en) 11, 13- modified schistosoxins for pain treatment
IL264049A (en) Compounds, preparations and methods for treating the disease
IL264156A (en) Compounds, preparations and methods for treating the disease
WO2017117070A8 (fr) Composés deutérés pour le traitement du cancer et de maladies et troubles associés, et compositions et méthodes associées
WO2015179559A3 (fr) Composés de pyrazole, procédés de production et utilisation
IL258471A (en) 11,13-modified saxitoxins for the treatment of pain
WO2016149401A3 (fr) Carbamates de pipérazine et procédés de préparation et d'utilisation de ceux-ci
WO2017136450A3 (fr) Composés et méthodes de traitement de maladies médiées par l'arn
WO2015001504A3 (fr) Formulations d'anticorps et procédés correspondants
SI3672954T1 (sl) Spojine, njihove soli in njihova uporaba za zdravljenje bolezni
WO2017106346A3 (fr) Anticorps neutralisants le virus de l'immunodéficience humaine
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
WO2015171610A3 (fr) Sulfonamide de tétrahydroquinoline et composés apparentés destinés à servir d'agonistes de rory et pour le traitement de maladies
HK1246286A1 (zh) Lrrk2抑制剂及其制备和使用方法
EA201790766A1 (ru) Новые соединения метилпиперидина, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1
HK1253734A1 (zh) 用作RORγ激动剂和用於治疗疾病的芳基二氢-2H-苯并[B][1，4]恶嗪磺酰胺和相关化合物
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
PH12019501690A1 (en) Pyrimidine compound and pharmaceutical use thereof
WO2018023072A3 (fr) Composés et compositions, et utilisations associées
WO2015066302A3 (fr) Compositions, méthodes d'utilisation et méthodes de traitement
WO2015015378A3 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
HK1259441A1 (zh) 包含btk抑制剂的制剂/组合物
WO2016057683A3 (fr) Nouveaux anticorps anti-nodaux et méthodes d'utilisation de ceux-ci
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16876381

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16876381

Country of ref document: EP

Kind code of ref document: A1